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a b s t r a c t / I m p l e m e n t a t i o n L e s s o n s
 Engaging stakeholders in the research process has the potential to improve quality of care and the
patient care experience.
 Online patient community surveys can elicit important topic areas for comparative effectiveness
research.
 Stakeholder meetings with substantial patient representation, as well as representation from health
care delivery systems and research funding agencies, are a valuable tool for selecting and reﬁning
pilot research and quality improvement projects.
 Giving patient stakeholders a deciding vote in selecting pilot research topics helps ensure their ‘voice’
is heard.
 Researchers and health care leaders should continue to develop best-practices and strategies for
increasing patient involvement in comparative effectiveness and delivery science research.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Diabetes mellitus is a chronic health condition affecting more
than 29 million people in the United States.1 Diabetes has a profound
negative impact on patient clinical outcomes and quality of life, and
is costly to individual patients, their families, and society at
large.2,3,4,5,6,7 Diabetes poses enormous challenges for both indivi-
duals with diabetes and the health care system. Individuals and their
caregivers must manage diet, exercise, medications, and self-
monitoring on a daily basis.8 In turn, the health care system must
coordinate the efforts of multiple clinical disciplines to support
patients and prevent serious and costly complications.
Comparative effectiveness research (CER) has the potential to
improve the effectiveness and safety of diabetes care. The key
goals of CER are to enhance the ability of patients, providers,
delivery systems, and policy-makers to make evidence-based
health care decisions, and to improve health care delivery and
outcomes.9 Patient-centered outcomes research (PCOR) is a type of
CER that places a strong emphasis on input from a wide variety of
health care stakeholders, especially patients, into research design,
conduct, analysis, and translation.10 Many experts have suggested
that PCOR's emphasis on stakeholder input into the research
process makes research more robust and relevant, and increases
the wide-scale implementation of evidence-based ﬁndings into
health care practice.10,11 The creation of the Patient Centered
Outcomes Research Institute (PCORI) through the passage of the
Affordable Care Act (ACA) in 2010 underscores the commitment of
policy makers to involve patient stakeholders in PCOR,10 and
PCORI's “Methodology Standards” speciﬁcally require that inves-
tigators provide evidence of patient involvement in creating
research questions and appropriate study designs.12
Despite the call for increasing the involvement of patients and
other stakeholders in the research process, there are very few
speciﬁc guidelines or strategies for health care researchers devel-
oping plans to actively engage stakeholders in the research design
process. Methods and best-practices for obtaining stakeholder
guidance on shaping critical CER questions for improving patient
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care, particularly for diabetes and other chronic conditions, are
largely unknown.13 The purpose of this paper is to outline an
evidence-based process for seeking input from patients and other
stakeholders in shaping critical CER questions for diabetes. This
process may provide a useful, replicable template for other
researchers seeking to engage stakeholders in the CER design
and implementation process.
2. Organizational context
The SUrveillance PREvention and ManagEment of Diabetes
Mellitus (SUPREME-DM) network was funded by the Agency for
Health Care Research and Quality (AHRQ) from 2010 to 2013
through AHRQ's “PRospective Outcome Systems using Patient-
speciﬁc Electronic data to Compare Tests and therapies (PRO-
SPECT)” initiative to develop and enhance CER data infrastructure
and methods. The aims of the original SUPREME-DM study were
to develop a multi-site data resource and investigator network for
conducting high quality CER in diabetes,14 and to leverage this
data resource to conduct surveillance and CER studies. SUPREME-
DM studies include efforts to better deﬁne the incidence and
prevalence of diabetes in adults and youth,15,16,17,18 assess tem-
poral trends in diabetes complications, evaluate patterns of pre-
scription medication use, initiation, intensiﬁcation,19,20,21 describe
racial and ethnic disparities in care, evaluate quality measures,22
examine pediatric diabetes care transitions, and advance CER
methods for diabetes studies.23,24,25,26 SUPREME-DM also con-
ducted an observational CER study comparing the effectiveness of
different counseling and referral strategies for women with gesta-
tional diabetes mellitus (GDM), and a cluster randomized CER trial
of telephone outreach to improve adherence to newly-prescribed
diabetes medications.
The SUPREME-DM CER data resource for conducting these
studies is known as the DataLink, which includes a deﬁned
population of almost 1.3 million patients with diabetes across 11
HMO Research Network (HMORN) integrated health care delivery
systems in the US.14 The DataLink is a robust, geographically
distributed research resource that combines patient demographic,
health care utilization, diagnosis, procedure, medication, and
laboratory data from EHR and other clinical and administrative
databases. While the DataLink leverages diverse clinical data
sources to advance CER in diabetes care and prevention, it
currently includes few patient-reported outcomes (e.g. self-
reported depression or diabetes distress measures are not avail-
able), and the studies conducted as part of the original SUPREME-
DM grant were designed and implemented without input from
stakeholders outside of the research team.
3. Personal context
Kaiser Permanente (KP) Colorado is the lead site for the
SUPREME- DM study, with John Steiner, MD, MPH, Senior Director
of the KP Colorado Institute for Health Research, serving as
Principal Investigator, and Andrea Paolino, MA, serving as the
study's senior project manager. Dr. Steiner and Ms. Paolino worked
closely with a subset of original SUPREME-DM research team
members across 6 sites (Jay Desai, PhD, Emily Schroeder, MD PhD,
Katherine Newton PhD, Jean Lawrence ScD MPH MSSA, Gregory
Nichols PhD, Patrick O’Connor, MD MPH, and Julie Schmittdiel
PhD) to develop and implement a strategy to enhance SUPREME-
DM's capabilities to conduct patient-centered CER in diabetes.
4. Challenge/problem
In 2013, AHRQ released a ‘limited competition” Funding
Opportunity Announcement (FOA) for grantees from PROSPECT
and other large, AHRQ-funded CER research grants. This “Enhan-
cing Investments in Comparative Effectiveness Research
Resources” FOA called for proposals to use a stakeholder engage-
ment process to “(1) understand stakeholder needs in order to
develop new comparative effectiveness research questions for
which future research could ﬁll important knowledge gaps and
generate critical insights on the clinical effectiveness and com-
parative clinical effectiveness of health care interventions;
(2) enhance the current data infrastructure and move toward
sustainability through developing the ability to address these
additional stakeholder-relevant questions.” The proposals were
designed to fund primary data collection (including stakeholder
input) and exploratory pilot projects, and were required to have a
full project timeline no longer than 18 months.
Upon receiving an award through this mechanism in Septem-
ber 2013, our ﬁrst challenge was to develop a stakeholder
engagement process that would provide meaningful insight into
the key patient-centered questions for diabetes CER. Our second
challenge was to use this information to develop CER/PCOR pilot
projects that would help enhance the SUPREME DM DataLink's
usefulness for conducting patient-centered research, and facilitate
the DataLink's long-term sustainability. We set out to create a
strategy to include patients in outlining critical needs in CER/PCOR
that was innovative, comprehensive, meaningful, and fast, and
that would provide a template for patient stakeholder engagement
that could be used by the SUPREME-DM research team and others
in future research.
5. Solution
We developed a 5-step approach to engaging a diverse set of
stakeholders to help us identify and prioritize CER questions that
are most relevant to diabetes care and prevention, and guide the
enhancement of the infrastructure and sustainability of the Data-
Link: a diagram outlining these steps is included as Fig. 1. This
participatory research-based process11 was modeled on ﬁve key
principles of engaging a wide range of stakeholders in CER:
ensuring balance among stakeholders; helping stakeholders under-
stand their role in the process; providing neutral, expert facilitators
for key discussions, and engaging participants throughout the
research process.27 In addition, we sought to combine both quali-
tative and quantitative methods to gather stakeholder input.13 Our
ﬁrst step was to develop and administer an internet-based survey of
Fig. 1. Five step process to design pilots for diabetes CER/PCOR research.
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an online community of diabetes patients to identify key challenges
in managing their diabetes. The second step was to conduct an in-
person stakeholder meeting to assess what patients, clinicians,
health care leaders, and policy-makers perceived as the critical
knowledge gaps in diabetes, and needs for translating known
evidence into optimal diabetes care. The research team then reﬁned
the domains obtained through the ﬁrst two steps and used them to
create 15 concepts for pilots to enhance the DataLink infrastructure
for CER/PCOR (Step 3), and select 5 pilot concepts from this list
based on pre-speciﬁed criteria (Step 4). In the ﬁfth and ﬁnal step,
these 5 concepts were taken back to the stakeholders, who voted to
determine which 3 pilots the SUPREME-DM research team would
implement in the ﬁnal phase of the process. Each of these ﬁve steps
is described in detail below.
5.1. Step 1: online patient community survey
We set out to ensure that the voices of patients ﬁgured
prominently in our stakeholder engagement process by ﬁrst
conducting an online survey of individuals with diabetes to elicit
patient-centered priorities for research in diabetes care. We
believed that this broad-based approach was likely to identify a
wide range of research priorities from a thoughtful and engaged
group of individuals with diabetes. We selected this approach over
more traditional ﬁrst steps such as conducting focus groups with
small numbers of individuals because we felt a quantitative
approach would be more representative and likely to yield a
greater number of ideas for discussion at the in-person stake-
holder panel meeting.
To implement the survey, we collaborated with PatientsLi-
keMes (PLM), a for-proﬁt online platform and social network for
individuals living with chronic conditions that offers tools for
disease tracking, data sharing with peers, and the opportunity to
participate in research studies.28 PLM facilitates virtual commu-
nities of over 200,000 individuals with a wide range of health
conditions; more than 11,000 PLM members are self-identiﬁed as
having diabetes.
The SUPREME-DM team designed a survey that captured
standard demographics and addressed patient experience in the
key areas of (1) getting diabetes care (e.g. ability to see specialists);
(2) communication (e.g. shared decision making); (3) medication
issues (e.g. insulin use); (4) lifestyle management (e.g physical
activity); and (5) social engagement (e.g. social support). These
domains were selected based on a scan of the literature, and
through review of commonly-used domains in other large-scale
surveys of diabetes patients (e.g. The Behavior Risk Factor Surveil-
lance System (BRFSS)). In order to elicit patient preferences,
questions were worded to assess how important each diabetes
care and management issue was for the individual patient living
with diabetes. Each topic domain was preceded by the prompt
“We want to hear which questions about [domain heading] are
most important to you right now. Please tell us which of these
concerns about diabetes impacts you personally, and how difﬁcult
each one makes your life.” The ﬁve response options included: not
difﬁcult, a little difﬁcult, somewhat difﬁcult, very difﬁcult, and
does not apply. We also included open-ended questions to allow
patients to further express their experiences and concerns living
with diabetes. A ﬁnal copy of this survey is included as an
Appendix.
PLM emailed survey invitations to its online community
members that had previously self-identiﬁed as having diabetes
in January 2014. Participation was voluntary and anonymous, and
patients were told that the results would be used to shape a CER
research agenda for diabetes. The survey was ‘open’ for completion
for 3 weeks; patients who did not respond to the initial invitation
were sent up to two emailed reminders within 14 days. A total of
320 PLM members completed the survey (31% of the 1044 who
opened the email invitation); survey respondents were older,
more likely to have Type 1 diabetes, and more likely to be female
compared with non-respondents.
The KP Colorado Institutional Review Board (IRB) determined
this survey did not fall under the jurisdiction of human subjects
research since the work was hypothesis generating (i.e., not
designed to test a hypothesis or answer a speciﬁc research
question), and there was no collection or use of private, identiﬁ-
able protected health information.
The de-identiﬁed responses to this online assessment were
analyzed by the SUPREME-DM study team by reporting the range
of responses for each question. Variation in responses was exam-
ined by key patient characteristics such as age, gender, employ-
ment status, health status, depression, and type of diabetes (type
1 vs. type 2). We presented a broad overview of these results to the
full stakeholder panel meeting in Step 2.
5.2. Step 2: in-person stakeholder meeting
We recruited a panel of stakeholders that included one repre-
sentative from each of the organizations listed in Table 1. We
sought the input of advocacy groups representing diabetes
patients, clinicians, and stakeholders from the leadership of health
systems that design and implement population-based care and
prevention for diabetes. In addition, we included funders of CER as
part of the stakeholders group, since they represented the per-
spective of those most likely to fund patient-centered PCOR
projects in diabetes informed by this process. We also invited
one government regulatory agency representative who was unable
to attend.
Since we considered people living with diabetes to be the most
crucial stakeholders in determining the key questions for patient-
centered CER in diabetes, we set a goal of recruiting 6–8 patients
with diabetes to serve on the stakeholder group in order to help
ensure a balance between patient perspectives and the perspec-
tives of the organizational stakeholders. Adults with diabetes were
selected from the membership of the Kaiser Permanente Mid-
Atlantic Region (which encompasses Washington, DC, Maryland
and Northern Virginia) since the in-person stakeholder meeting
was held in Washington, DC.
A list of potential patient participants for the in-person stake-
holder meeting was drawn from KP Member Voice (KPMV), an
online panel of over 21,000 KP members nationwide who agree to
Table 1
Stakeholder representation.
Federal agencies
Agency for Healthcare Research & Quality (AHRQ)
Centers for Disease Control and Prevention (CDC)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
US Department of Veterans Affairs (VA)
Membership/Advocacy organizations
American Association of Diabetes Educators (AADE)
American Diabetes Association (ADA)
JDRF (formerly known as Juvenile Diabetes Research Foundation)
Disadvantaged populations
Centers for American Indian and Alaska Native Health, Colorado School of
Public Health (University of Colorado at Denver)
Delivery systems
Group Health Cooperative (GHC)
Kaiser Permanente Northwest (KPNW)
Patients
Five Individuals with Diabetes and One Family Member from the Kaiser
Permanente Mid-Atlantic Region
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be contacted for activities such as online surveys and focus groups.
The project manager requested a list of KPMV panelists who were
members of KPMA with a diagnosis of Type 1 or Type 2 diabetes;
she requested a list with racial/ethnic representation that was
equally balanced on gender.
The project manager called potential participants to assess
their interest in being a stakeholder panelist and in actively
participating in group discussions. As with the PLM work, the
KPCO IRB determined that this patient involvement did not require
IRB oversight, since the patients were engaged as stakeholders and
not study subjects. Potential participants were told they would be
paid $200 for the 8 h in-person meeting and $50 for attending two
webinars ($25 each) to be conducted after the meeting in
Washington, DC, and that their travel costs would be reimbursed.
Five individuals living with diabetes agreed to attend the in-
person meeting; in addition, a spouse of one of the individuals
with diabetes agreed to participate. Ultimately ﬁve individuals
with diabetes and one family member comprised 6 of the 16
stakeholders on the panel (38%).
In order to prepare stakeholders for the discussion, we con-
ducted two sets of stakeholder pre-meetings. Non-patient stake-
holders attended an orientation Webinar in February 2014. This
meeting was held twice (content and facilitator identical in each)
in order to make attending as convenient as possible. This meeting
provided an orientation to SUPREME-DM and the DataLink, and a
description of CER/PCOR developed by PCORI and other
experts.9,29 This pre-meeting also reviewed the participatory
research principles underlying our strategy for the stakeholder
process,11 and placed a speciﬁc emphasis on explaining the
importance of incorporating patient opinions and priorities into
the process. We strongly encouraged an atmosphere of listening
and learning during the meeting.
The patients also received an orientation to the stakeholder
meeting during a breakfast meeting on the morning of the
stakeholder meeting, which provided an opportunity for the
patients to meet each other and become familiar with the facil-
itator and the research team. We engaged in a discussion of the
importance of including patient perspectives into the research
process, emphasizing the critical value of their perspectives and
encouraging them not to be intimidated by the organizational
stakeholders in the room.
The 6-h meeting with the stakeholder panel and the research
team was held at the Kaiser Permanente Center for Total Health in
Washington, DC on March 14, 2014. To ensure all stakeholders had
equal opportunities to engage during the meeting, we enlisted a
strong, experienced external meeting facilitator: Erin Holve, PhD,
MPH, a Senior Director at AcademyHealth and principal investi-
gator of the Electronic Data Methods (EDM) Forum grant from
AHRQ 30. The ﬁndings from the PLM survey were presented during
this meeting to help spark conversation around patient priorities
for diabetes care improvements and diabetes research. This pre-
sentation discussed the survey methods; described the survey
population's demographic and clinical characteristics; and pre-
sented patient-reported areas presenting care difﬁculties: results
were shown as univariate distributions, and also stratiﬁed by Type
1 vs. Type 2 diabetes. Throughout the day, patient stakeholders
were given the ﬁrst opportunity to respond to questions that were
raised, and patient responses were elicited by the meeting facil-
itator: the patient stakeholders participated actively in each
portion of the meeting's conversations. By encouraging the parti-
cipation of all stakeholders, acting as an impartial mediator, and
clarifying the proposals and options on each speciﬁc issue, the
facilitator worked with the panel to reach consensus with all the
stakeholders, including the patients, on a broad set of potential
diabetes CER research topics, including a discussion about which
of these topics could potentially translate into SUPREME-DM data
infrastructure enhancements. Selected topics included pragmatic
clinical trials, system-level studies, diabetes treatments (reasons
for intensiﬁcation, non-adherence, etc.), patient-reported out-
comes, patient education, and sustainability (Table 2).
5.3. Step 3: reﬁne stakeholder domains into 15 CER pilot projects
After the in-person meeting, the research team reviewed these
high-priority diabetes CER topics in Table 2 to identify those that
might be most suited for the SUPREME-DM data infrastructure,
and/or potentially lead to improvements in the patient-
centeredness of the SUPREME-DM data infrastructure, through
development into pilot studies. The budget and timeline for the
grant allowed for up to 3 pilot studies to be conducted between
the end of the pilot selection process (at roughly the 9 month
mark) and the end of the study (18 months). The research team
members were asked to submit speciﬁc research pilot ideas within
3 weeks of the ﬁrst stakeholder meeting, and brieﬂy describe how
pilot ideas were aligned with 6 pilot study selection criteria most
consistent with the goals of the AHRQ FOA: innovation; feasibility/
affordability; maximized use of the DataLink; patient-centered-
ness; potential for future funding (i.e. sustainability); and the
likelihood that pilot ﬁndings could be published and lead to
generalizable knowledge.
A total of 15 pilot research projects were submitted by the
research team for initial consideration and ranking by the research
team. The project manager distributed these concepts to the
research team, who were asked to rate each pilot on a scale of
1–5 (1 being the best) on each of the 6 criteria listed above, and to
provide an ‘overall’ score from 1 to 5 for each concept.
5.4. Step 4: select top 5 CER pilot project concepts
On April 14, 2014 (one month after the stakeholder meeting),
the research team held a meeting to review the 15 pilot ideas and
their scores, and discuss which pilot concepts were the strongest
candidates for pilot research studies. At the end of this meeting,
the researchers selected the 5 pilot ideas that were most aligned
with the selection criteria (including patient-centeredness) out-
lined above; the determination was based on the collective
opinion of the research team. These potential studies were
Table 2
List of stakeholder priority diabetes CER topics.
1. Studying clinical subgroups (phenotypes)
2. Increasing patient-guided treatment/shared decision-making
3. Improving/collecting information on care management approaches,
coordination of care
4. Collecting information from patients via Interactive Voice Response (IVR)
5. Understanding patient and provider factors that play a role in intensiﬁcation
of diabetes treatment regimens
6. Developing pragmatic trials to improve diabetes care for the elderly and
Type 1 DM
7. Targeting care to “high risk” individuals based on impairments in physical or
mental health status (those in fair or poor health)
8. “Un-complicating” diabetes care through simplifying/coordinating
medication regimens
9. Providing diabetes education and support in real-time through peers and/or
professionals
10. Integrating clinical decision support into care and existing work ﬂows
11. Developing valid, reliable data systems on diabetes education referral and
follow-up
12. Assessing non-adherence as a potential ‘alert’/marker of diabetes distress
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presented at the second stakeholder meeting described in Step
5 below.
5.5. Step 5: stakeholder meeting 2: selecting the ﬁnal CER pilot
projects
On May 7, 2014, each of the 5 top-ranking pilot ideas were
presented to the stakeholders at a webinar-based meeting.
Approximately 50% of the attendees present at the in-person
meeting attended, including 50% of the patients. The purpose of
the meeting was to discuss the extent to which the pilot ideas
addressed the diabetes CER priorities gleaned from the initial
stakeholder meeting, and to conduct rank voting on which 3 of the
5 should be approved and pursued in the second phase of the
grant. This ‘rank voting’ approach to prioritization, which gave
each stakeholder representative the opportunity to rank each
project in a hierarchy on an ordinal 1–5 scale (with 1 being the
highest priority and 5 being the lowest priority) is consistent with
recommended methods for eliciting stakeholder preference
endorsed by both PCORI and AHRQ.31,32 Only one round of rank
voting was required to reach agreement on the top 3 prioritized
projects; the 3 selected CER pilot projects based on this voting
process are presented in Table 3.
At the end of the webinar, the patient stakeholders gave the
research team positive feedback on the extent to which they felt
their voices were heard in the process. One patient said of the
project ideas proposed, “It's a good list.” Another patient said, “I
think this is a good representation of what we discussed at the
meeting in March. I feel that all areas have been covered, and I think
it…stands out that the team has done an excellent job in breaking
down the information and…meeting the needs of what needs to be
done.” We also received positive feedback about the process
overall, with patients telling us “It's been a privilege and an honor
to participate in this panel, and I would gladly do it again if asked,”
and “Thank you for asking me to participate.”
6. Unresolved questions and lessons for the ﬁeld
The ﬁnal step in our stakeholder engagement process will be to
present the results from the 3 pilot research projects at the end of
the study (March 2015), to share our ﬁndings, discuss plans for
using the pilot results to pursue larger research projects, and
obtain feedback on how to continue to develop the DataLink as a
sustainable resource for diabetes CER/PCOR. In addition, we plan
to continue our engagement with this stakeholder group by
creating an ‘advisory board’ that can provide feedback on future
research projects as they are developed.
Our hope is that these pilot projects shaped by patient and
organizational stakeholder priorities will lead to research questions
of interest to PCORI, AHRQ, NIDDK, and other agencies with a strong
interest in stakeholder engagement. While we strongly believe that
our investment in ongoing stakeholder engagement will lead to
research that is more relevant to patients, and more likely to be
implemented and disseminated by providers and health care delivery
systems, we will need more time for this belief to be fully tested.
Our approach to assessing diabetes patient priorities and con-
cerns through a broad-based online survey yielded a range of
thought-provoking ideas that would likely not have emerged
through in-person stakeholder meetings alone, and the ﬁndings
from our survey signiﬁcantly informed and enriched the stake-
holder meeting process. This ‘hybrid’ process of combining in-
person techniques with internet-based approaches combined the
advantages of large sample sizes with in-depth engagement and
perspectives 33. While we believe that this hybrid approach is novel
for diabetes research and care planning, and allows for a wide range
of input, we acknowledge that there may still be limitations to the
representativeness of the opinions that were gleaned from the
stakeholders that were willing to participate in either the survey or
the in-person meetings. While working with an online community
may not be the only way of gathering a wide range of patient
perspectives, we believe a broad-based assessment of the research
domains relevant to patients is critical to formulating impactful
Table 3
Selected diabetes CER pilot studies.
Pilot research project Background Key aims Importance to CER/PCOR
Sustaining the SUPREME-DM
DataLink: preliminary data
for innovative proposals
Because of its size, the SUPREME-DM
database has large numbers of people in
various subgroups. However, we have not
fully explored the number of people in each
subgroup and how well we can follow them
over time.
1. Organize existing data for key subgroups
of interest (elderly, racial/ethnic subgroups,
obesity, prediabetes), including
documenting available length of follow-up.
Funding requests require preliminary data
and innovative ideas. These tables would
show that we have the data available in
this unique and comprehensive data set in
order to answer CER/PCOR research
priorities from the stakeholder group that
can improve the lives of people living with
diabetes or those who may develop it.
2. Incorporate stakeholder priority 1
(Table 2)
Adding self-management and
healthy lifestyle counseling,
referrals, and follow-up
information to the SUPREME-
DM Data Link
Diabetes education is an important aspect of
diabetes treatment. We cannot currently
measure diabetes education encounters
(that is, when patients receive this
education) in the SUPREME-DM data.
1. Conduct interviews of health plan
employees (clinicians, educators, health
information technologists) to determine
how diabetes education referrals and
encounters are documented in the
electronic medical record. Conduct chart
reviews to see how accurate this
information is.
An important ﬁrst step for most studies of
diabetes education is the ability to identify
diabetes education encounters and
referrals. Diabetes education was a key
priority area for stakeholders.
2. Incorporate stakeholder priorities
9 and 11 (Table 2)
Building a patient-centered
tool to monitor hypoglycemia
events
Hypoglycemia (low blood sugar) symptoms
and events are often not well captured in
electronic medical records.
1. Design a method of surveying people
about how often they experience
hypoglycemia and what their symptoms are.
We could ask these questions by using
interactive voice response (IVR) or text
messaging. We would work together with
focus groups of individuals living with
diabetes to develop this system.
Hypoglycemia events can negatively affect
people's quality of life and impact
treatment choices. Hypoglycemia is an
important patient-reported outcome for
several potential funders. Collecting
hypoglycemia information from patients
via methods such as IVR and using it to
better coordinate and improve care were
priorities for our stakeholders.2. Incorporate stakeholder priorities
3,4,5 and 9 (Table 2)
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questions in CER/PCOR. Other options for gathering this information
might include conducting multiple semi-structured interviews;
examining existing national survey sources, or publications doc-
umenting other stakeholder processes. Another important advan-
tage of our particular process was the speed at which it could be
completed: the entire process of prioritization and identiﬁcation of
the ﬁnal ideas for pilot studies was completed within 6 months of
the ﬁrst research team project meeting.
Our project's timeline and budget did not allow for a full evaluation
of the impact of the stakeholder process on our outcomes, or of the
perceptions of the process by the stakeholders themselves; this type of
evaluation can be an important tool in understanding the overall
effectiveness of stakeholder engagement 34. However, as cited above
our patient stakeholders did give us informal feedback that they were
very satisﬁedwith the process (see Section 5). In addition, our research
team strongly believed that engaging stakeholders in designing
comparative effectiveness research had a signiﬁcant impact on the
pilot research studies that will be conducted using the SUPREME-DM
DataLink. For example, when we initially began our stakeholder
process, there had been no discussion among the research team about
pursuing research in diabetes education, or to adding variables about
diabetes education classes and referrals to the DataLink (priorities
9 and 11 in Table 2). It was the direct input of our stakeholders
(particularly our patient stakeholders) that prompted the research
team to address this critical topic. In addition, the stakeholder input on
the importance of gathering patient-reported information on hypo-
glycemia in ways that were convenient and acceptable to patients
signiﬁcantly shaped the pilot work in this area. These examples were
important reminders that in order for research to truly address patient
needs, researchers ﬁrst need to go directly to the patients themselves
to both assess and to better understand their concerns. CER/PCOR
investigators should continue to work with providers and delivery
systems to develop rapid, sustainable approaches to meaningfully
involve patients in their efforts to develop patient-centered, learning
health care systems.35,36,37,38
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Appendix
PatientsLikeMe Online Survey
Diabetes Research - What is important to you?
Hi USERNAME,
This one’s a little bit different. This is us and our new partner in
this project Kaiser Permanente learning more about diabetes from
you – in your own words.
We’ll still ask about a few basics, but we’re also going to leave
some questions open ended so you can add in your own com-
ments. Tell us what you ﬁnd difﬁcult about diabetes treatment and
care, and what you think is important for researchers to look at
down the road.
Click below to get started on this new survey. We’re listening.
Thanks for sharing!
PatientsLikeMe and Kaiser Permanente
Thanks for participating in this survey. It should take
between 15 and 20 minutes to complete. And don’t forget,
there are a bunch of questions with comment boxes where you
can add any additional answers or thoughts. You can come
back and ﬁnish the survey at any time by clicking on your
invitation message.
Your voice will help everyone learn more about diabetes
treatment and care. You’ll also help doctors and researchers
understand what areas of diabetes research matter most to
you. As always with our research, we’ll be sure to share the
results with the community. Let’s get started.
BasicInfo (Demographics)
Sex
Birth date
Country
Ethnicity
Race
Education level
Section 1
Would you say your general health is:
Excellent (Value: 1)
Very good (Value: 2)
Good (Value: 3)
Fair (Value: 4)
Poor (Value: 5)
Don't know/Not sure (Value: 6)
What type of diabetes do you have?
Type 1 (Value: 1)
Type 2 (Value: 2)
Other (Value: 3)
Not sure (Value: 4)
What is your primary activity?
Employed for wages (Value: 1)
Self-employed (Value: 2)
Out of work for one year or more (Value: 3)
Out of work for less than one year (Value: 4)
Homemaker (Value: 5)
Student (Value: 6)
Retired (Value: 7)
Unable to work (Value: 8)
New Section
You said you had some other type of diabetes.
Show if: (TYPE_DM IS '3')
What type of diabetes do you have?
Free-form text
New Section
How old were you when a doctor, nurse, or other health
professional told you (or your parents) that you have diabetes?
If you don't know your exact age, just make your best guess.
Number
Are you currently taking any medications to treat your
diabetes?
Yes (Value: 1)
No (Value: 2)
Don't know (Value: 6)
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New Section
Show if: (CURRENT_ANYMED IS '1')
Are you currently taking insulin?
Yes (Value: 1)
No (Value: 2)
Don't know (Value: 6)
New Section
Show if: (CURRENT_INSULIN IS '1')
How old were you when you ﬁrst started taking insulin at
least once a day? If you do not know your exact age, just make
your best guess.
Number
New Section
Show if: (CURRENT_ANYMED IS '1')
Are you currently taking medications (other than insulin) to
lower your blood sugar?
Yes (Value: 1)
No (Value: 2)
Don't know (Value: 6)
Have you ever been told by a doctor, nurse, or other health
professional that you have any of the conditions described
below?
High blood pressure?
 High blood cholesterol?
 A depressive disorder, including depression, major depres-
sion, dysthymia, or minor depression?
 A heart attack, also called a myocardial infarction?
 Angina or coronary heart disease?
 A stroke?
 Kidney disease because of your diabetes?
 Diabetes has affected your eyes or that you had retinopathy?
 Diabetes has affected your nerves/nervous system or that
you have neuropathy?
Yes (Value: 1)
No (Value: 2)
Don't know (Value: 6)
New Section
Have your ever had any sores or irritations on your feet that
took more than four weeks to heal?
Yes (Value: 1)
No (Value: 2)
Don't know (Value: 6)
We want to hear which questions about your diabetes care
are most important to you right now. Please tell us which of
these concerns about diabetes impacts you personally, and how
difﬁcult each one makes your life. You can give the same
answer for more than one item.
What do you personally ﬁnd difﬁcult about getting the
diabetes care that you need?
 Having a regular doctor or other health care provider for my
diabetes.
 Seeing specialty providers such as endocrinologists, diabetes
educators, dieticians, etc.
 Getting to the ofﬁce of my doctor or other health care
provider.
 Getting an appointment at a doctor's ofﬁce or clinic as soon
as I think one is needed.
 Getting or keeping health insurance coverage.
 Paying for my diabetes visits, treatment or supplies.
Not difﬁcult (Value: 1)
A little difﬁcult (Value: 2)
Somewhat difﬁcult (Value: 3)
Very difﬁcult (Value: 4)
Does not apply (Value: 6)
New Section
Please tell us more about what you personally ﬁnd difﬁcult
about getting the diabetes care you need.
Free-form text
What do you personally ﬁnd difﬁcult about communicating
with your doctors or other health care providers? You can give
the same answer for more than one item.
 Getting a response from my doctor or other health care
professionals in a timely manner.
 Using e-mail, texting or the Web to reach my doctor or other
health care provider.
 Making choices about diabetes medicine and other treat-
ments that I think are best for me.
 Talking with my doctor or health care provider about the
pros and cons of each choice for my treatment.
 Working with my doctor to set personal goals for my
treatment.
 Feeling that my doctor or other health care providers
respect, understand, and listen to me.
 Getting easy to understand instructions about taking care of
my diabetes.
 Understanding current and future health risks of my dia-
betes, such as its effects on my heart, eyes, kidneys, feet, or
mental health.
 Making sure that all my diabetes care providers are working
together for me.
Not difﬁcult (Value: 1)
A little difﬁcult (Value: 2)
Somewhat difﬁcult (Value: 3)
Very difﬁcult (Value: 4)
Does not apply (Value: 6)
New Section
Please tell us more about what you personally ﬁnd difﬁcult
about communicating with your doctors or other health care
providers.
Free-form text
What do you personally ﬁnd difﬁcult about managing your
medications for diabetes and other conditions? You can give
the same answer for more than one item.
 Taking insulin.
 Taking diabetes medications (other than insulin) as
prescribed.
 Taking medications for cholesterol or blood pressure as
prescribed.
 Managing side effects or interactions between my
medications.
Not difﬁcult (Value: 1)
A little difﬁcult (Value: 2)
Somewhat difﬁcult (Value: 3)
Very difﬁcult (Value: 4)
Does not apply (Value: 6)
New Section
Please tell us more about what you personally ﬁnd difﬁcult
about managing your medications for diabetes.
Free-form text
What other things do you ﬁnd difﬁcult about taking care of
your diabetes and other conditions? You can give the same
answer for more than one item.
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 Testing my blood sugars ("ﬁngersticks" or continuous glu-
cose monitoring).
 Eating a healthy diet.
 Getting enough physical activity.
 Managing my weight.
 Managing stress.
 Getting enough support from my family and friends.
 Diabetes interfering with my work.
 Diabetes interfering with my social activities with family,
friends, neighbors or groups.
 Trying to not be a burden to others.
 Using alternative medicine (natural herbs, acupuncture,
meditation, etc).
Not difﬁcult (Value: 1)
A little difﬁcult (Value: 2)
Somewhat difﬁcult (Value: 3)
Very difﬁcult (Value: 4)
Does not apply (Value: 6)
New Section
Please tell us more about what you personally ﬁnd difﬁcult
about taking care of your diabetes and other conditions.
Free-form text
How important are the following things to you?
 Feeling as well as possible.
 Living as long as possible.
 Being able to do as many activities as possible.
Not important (Value: 1)
A little important (Value: 2)
Somewhat important (Value: 3)
Very important (Value: 4)
New Section
Are there any other challenges or concerns about your
diabetes care that you want us to know?
Free-form text
Thinking about when you were ﬁrst told you had diabetes,
what was or would have been most helpful for you to know
about your diabetes at that time?
Free-form text
Thinking about 3-5 years into the future from now, what do
you feel will be important to learn or know about your
diabetes? Why?
Free-form text
Final questions! Please tell us just a little more about you.
About how much do you weigh (in pounds) without shoes?
Number
About how tall are you without shoes?
Do you have any last comments about this survey?
Free-form text
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